Acella Pharmaceuticals, LLC

Form 483 issued March 29, 2019 · Alpharetta, Georgia

Inspection
Mar 25 – Mar 29, 2019
Investigator
Vanessa E. Coulter
Observations
2
Pages
3
FEI number
3006691461

In short: On March 29, 2019, FDA issued a Form 483 with 2 observations to Acella Pharmaceuticals, LLC in Alpharetta, Georgia (FEI 3006691461) after an inspection that ran Mar 25 – Mar 29, 2019. The investigator was Vanessa E. Coulter. The most-cited regulation is 21 CFR 314.81 (other postmarketing reports).

What FDA observed

Preview: the opening words of each observation

Dashed: section inferred by FDA Intel and checked against the regulation text

  1. 01

    An annual report was not submitted within 60 days of the anniversary date of U.S. approval…

  2. 02

    Not all annual periodic adverse drug experience reports have been submitted within 60 days of the…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Acella Pharmaceuticals, LLC?

FDA listed 2 observations on this Form 483. The most-cited regulation is 21 CFR 314.81 (other postmarketing reports). The opening words of each observation are shown on this page.

Who inspected Acella Pharmaceuticals, LLC?

Vanessa E. Coulter is named on this Form 483, for the inspection of Mar 25 – Mar 29, 2019. Each investigator has a profile showing what they cite most.

When was Acella Pharmaceuticals, LLC inspected by FDA?

The inspection ran Mar 25 – Mar 29, 2019, and the Form 483 is dated March 29, 2019.

How do I get the full Form 483 for Acella Pharmaceuticals, LLC?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free